Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital

被引:47
|
作者
O'Sullivan, JM
Norman, AR
Cook, GJ
Fisher, C
Dearnaley, DP
机构
[1] Royal Marsden Hosp, Royal Marsden NHS Trust, Inst Canc Res, Acad Unit Radiotherapy & Clin Oncol, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden Hosp, Inst Canc Res, Dept Comp & Informat, Sutton SM2 5PT, Surrey, England
[3] Royal Marsden Hosp, Inst Canc Res, Dept Nucl Med, Sutton SM2 5PT, Surrey, England
[4] Royal Marsden Hosp, Inst Canc Res, Dept Histopathol, Sutton SM2 5PT, Surrey, England
关键词
radionuclide imaging; prostatic neoplasms; bone metastases; Gleason scoring;
D O I
10.1046/j.1464-410X.2003.04480.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To determine if it is possible to exclude staging bone scans in a greater proportion of patients if more consideration is given to T stage and Gleason score, as recent guidelines from the National Institute of Clinical Excellence state that routine staging bone scans for prostate cancer are unnecessary in patients with a prostate specific antigen level (PSA) of < 10 ng/mL and Gleason scores of < 8. We identified a cohort of consecutive patients with untreated prostate cancer who had a staging isotope bone scan between 1 January 1995 and 31 December 2000, who were not on hormone therapy, who had their PSA estimated within 30 days of the scan, and who had histologically confirmed prostate cancer on biopsy reviewed at the Royal Marsden. Data were analysed according to Gleason score, major Gleason grade, clinical T-stage and PSA level. In all, 420 patients were identified who fulfilled the criteria for inclusion; 67 scans (16%, 95% confidence interval, CI, 13-20%) were positive. Of the 187 scans taken in patients with a PSA level of less than or equal to 20 ng/mL, stage < T4 and Gleason < 8 (with major Gleason grade < 4), two (1%, 0.3-4%) were reported as positive, giving a negative predictive value of 99% (95% CI 98.5-99.5%) for these criteria for avoiding the need for staging bone scans. In 116 patients (28%) with Gleason score 7, of whom 28 (24%) had positive scans, there was a statistically significant association between positive scans and a major Gleason pattern of 4 compared with 3. Isotope bone scans are an unnecessary part of staging of prostate cancer if the PSA level is less than or equal to 20 ng/mL, stage < T4 and Gleason score < 8, and should be omitted unless the major Gleason pattern is 4. The present results suggest that by considering the Gleason score and T stage, a larger proportion of patients with prostate cancer than previously thought could avoid a staging bone scan.
引用
收藏
页码:685 / 689
页数:5
相关论文
共 50 条
  • [1] Broadening the criteria for avoiding staging bone scans in prostate cancer: A retrospective study of patients at the Royal Marsden Hospital
    Sandblom, S
    Varenhorst, E
    BJU INTERNATIONAL, 2004, 93 (06) : 889 - 890
  • [2] Broadening the criteria for avoiding staging bone scans in prostate cancer: A retrospective study of patients at the Royal Marsden Hospital
    Thurairaja, R
    Barrass, B
    Mcfarlane, JP
    Persad, R
    BJU INTERNATIONAL, 2004, 93 (09) : 1358 - 1359
  • [3] A study on staging bone scans in newly diagnosed prostate cancer
    Ayyathurai, R
    Mahapatra, R
    Rajasundaram, R
    Srinivasan, V
    Archard, NP
    Toussi, H
    UROLOGIA INTERNATIONALIS, 2006, 76 (03) : 209 - 212
  • [4] Are staging bone scans necessary in patients with T3a prostate cancer? A multicentre study
    Whiting, Danielle
    Giona, Simone
    Yao, Mark
    Hassan, Roa
    Doan, Hong
    Karanjia, Rustam
    Hicks, James
    Eddy, Ben
    Madaan, Sanjeev
    Bott, Simon
    JOURNAL OF CLINICAL UROLOGY, 2025, 18 (01) : 69 - 72
  • [5] Bone scan in staging of prostate cancer - Criteria reevaluated
    Abbott, JT
    Ritenour, CWM
    Hall, J
    Alazraki, N
    Issa, MM
    JOURNAL OF UROLOGY, 2006, 175 (04): : 533 - 533
  • [6] A Retrospective Study of Patients with Malignant PEComa Receiving Treatment with Sirolimus or Temsirolimus: The Royal Marsden Hospital Experience
    Benson, Charlotte
    Vitfell-Rasmussen, Joanna
    Maruzzo, Marco
    Fisher, Cyril
    Tunariu, Nina
    Mitchell, Scott
    Al-Muderis, Omar
    Thway, Khin
    Larkin, James
    Judson, Ian
    ANTICANCER RESEARCH, 2014, 34 (07) : 3663 - 3668
  • [7] Staging CT scans in prostate cancer treatment: A retrospective audit.
    Burcombe, RJ
    Ostler, PJ
    Ayoub, AW
    Hoskin, PJ
    BRITISH JOURNAL OF CANCER, 1999, 80 : 68 - 68
  • [8] The role of staging CT scans in the treatment of prostate cancer: A retrospective audit
    Burcombe, RJ
    Ostler, PJ
    Ayoub, AW
    Hoskin, PJ
    CLINICAL ONCOLOGY, 2000, 12 (01) : 32 - 35
  • [9] Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
    Bianchini, Diletta
    Lorente, David
    Rescigno, Pasquale
    Zafeiriou, Zafeiris
    Psychopaida, Elena
    O'Sullivan, Hazel
    Alaras, Mervyn
    Kolinsky, Michael
    Sumanasuriya, Semini
    Fontes, Mariane Sousa
    Mateo, Joaquin
    Lopez, Raquel Perez
    Tunariu, Nina
    Fotiadis, Nikolaos
    Kumar, Pardeep
    Tree, Alison
    Van As, Nicholas
    Khoo, Vincent
    Parker, Chris
    Eeles, Rosalind
    Thompson, Alan
    Dearnaley, David
    de Bono, Johann S.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : E801 - E807
  • [10] Role of staging bone scans in the patients with newly diagnosed prostate cancer. Are the current guidelines acceptable?
    Thangavelu, Mohanarangam
    Kotb, Ahmed
    Gkekas, Chrysovalantis
    Yehia, Mohamed
    Walker, Jason
    BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 32 - 32